A Phase 2 interventional study of OSE-127 and Placebo in Ulcerative Colitis, sponsored by OSE Immunotherapeutics. Completed at 55 sites in 11 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-23.
Sponsored by OSE Immunotherapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 90 studies in Colitis, Ulcerative with a site in Bulgaria — 9 open to participants now, 24 under way, 16 of them phase 3. Colitis, Ulcerative · Bulgaria.
Among the 90 studies in Colitis, Ulcerative with a site in Bulgaria, this one is the 68th largest by enrollment of the 89 interventional ones that give a count, is one of 5 that started in 2020, is one of 41 in phase 2, and was the 56th registered.
1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.
Browse Colitis, Ulcerative studies →9 of the 90 studies in Colitis, Ulcerative with a site in Bulgaria are open now. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in Bulgaria, United States, Argentina and 30 more countries
Ages 18+
Sanofi · Sites in Bulgaria, United States, Argentina and 28 more countries
Ages 16–80
Takeda · Sites in Bulgaria, United States, Belgium and 11 more countries
Ages 2–17
Sanofi · Sites in Bulgaria, United States, Argentina and 25 more countries
Ages 16–80
Eli Lilly and Company · Sites in Bulgaria, United States, Austria and 20 more countries
Ages 18–70
A study can be open while its sites in Bulgaria have not opened yet or have stopped. Only those recruiting at a site in Bulgaria →
Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
90 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 49 · Phase 3 45 · Phase 4 1
First in 2007; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 136 is above the median of 70 across 1,239 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 280 across the 89 interventional studies, 104 across the 1 observational. Of the 65 that completed or were terminated, 51 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 90 have an industry lead sponsor. The 10 most frequent:
OSE Immunotherapeutics is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
OSE Immunotherapeutics has 2 studies filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
4 of the studies in Colitis, Ulcerative with a site in Bulgaria that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06589986Phase 3Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | 2027-01-30 |
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
| NCT07012395Spyre Therapeutics, Inc.A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis | 2027-06 |
| NCT06257875AbbVieA Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 90 studies in Colitis, Ulcerative with a site in Bulgaria, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group study in patients with moderate to severe active ulcerative colitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of moderate to severe active UC made at least 3 months before the screening visit. The diagnosis of UC must have been confirmed by endoscopy, with a minimal extent of 15 cm from anal margin and histology (Moderate to severe active UC is defined by a modified Mayo score between 4 and 9, inclusive. The modified Mayo score is defined by the addition of the rectal bleeding subscore, the stool frequency sub-score, and the endoscopic sub-score. Thus, to be included, a patient must have the following:
No previous biologic therapy (i.e., TNF antagonists, vedolizumab or ustekinumab) and prior or current UC documented medication history that includes at least 1 of the following:
OR
Previous or current biologic therapy
Exclusion Criteria:
The following laboratory results at screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
OSE-127 mAb antagonist to CD127 receptor (or IL-7Rα) intravenous infusion 3 total infusions, weeks 0, 2, and 6
Drug: OSE-127
OSE-127 mAb antagonist to CD127 receptor (or IL-7Rα) intravenous infusion 3 total infusions, weeks 0, 2, and 6
Drug: OSE-127
Normal saline intravenous infusion 3 total infusions, weeks 0, 2, and 6
Drug: Placebo
OSE-127 mAb antagonist to CD127 receptor (or IL-7Rα) intravenous infusion 7 total infusions, weeks 10, 14, 18, 22, 26, 30, and 34
Drug: OSE-127
mAb antagonist to CD127 receptor (or IL-7Rα)
Normal saline
Change From Baseline in Modified Mayo Score (MMS) at Week 10
The Mayo Score measures disease activity for UC. The modified questionnaire has 3 domains (instead of the usual 4): 2 with questions answered by the patient (stool frequency and rectal bleeding) and 1 answered by an endoscopist (mucosal appearance at endoscopy). Each domain is graded from 0 to 3, higher values representing a worse outcome. Total score for modified Mayo Score is calculated as the sum of the three sub-scores, and ranges from 0 to 9.
Time frame: From Baseline to Week 10
Clinical Remission Rate at Week 10
Clinical remission rate\*: percentage of participants in clinical remission, defined as MMS ≤ 2 points and no individual sub-score of \> 1 point and a rectal bleeding at 0. \*The clinical remission rate is reported with imputation.
Time frame: Week 10
Endoscopic Remission Rate at Week 10
Endoscopic remission rate\*: percentage of participants with an endoscopic remission, defined by an endoscopic Mayo sub-score = 0. \*The endoscopic remission rate is reported with imputation.
Time frame: Week 10
| Milestone | Lusvertikimab 850 mg, Induction Period | Lusvertikimab 450 mg, Induction Period | Placebo, Induction Period | Lusvertikimab 850 mg, Open-Label Extension Period |
|---|---|---|---|---|
| Started | 51 | 36 | 49 | 0 |
| Completed | 47 | 32 | 42 | 0 |
| Not completed | 4 | 4 | 7 | 0 |
| Milestone | Lusvertikimab 850 mg, Induction Period | Lusvertikimab 450 mg, Induction Period | Placebo, Induction Period | Lusvertikimab 850 mg, Open-Label Extension Period |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 120 |
| Completed | 0 | 0 | 0 | 104 |
| Not completed | 0 | 0 | 0 | 16 |
The Mayo Score measures disease activity for UC. The modified questionnaire has 3 domains (instead of the usual 4): 2 with questions answered by the patient (stool frequency and rectal bleeding) and 1 answered by an endoscopist (mucosal appearance at endoscopy). Each domain is graded from 0 to 3, higher values representing a worse outcome. Total score for modified Mayo Score is calculated as the sum of the three sub-scores, and ranges from 0 to 9.
| units on a scale | Lusvertikimab 850 mg | Lusvertikimab 450 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Modified Mayo Score (MMS) at Week 10 | -2.41 (-2.99 to -1.83) | -2.68 (-3.44 to -1.91) | -1.52 (-2.14 to -0.90) |
Clinical remission rate\*: percentage of participants in clinical remission, defined as MMS ≤ 2 points and no individual sub-score of \> 1 point and a rectal bleeding at 0. \*The clinical remission rate is reported with imputation.
| percentage of participants | Lusvertikimab 850 mg | Lusvertikimab 450 mg | Placebo |
|---|---|---|---|
| Clinical Remission Rate at Week 10 | 12.9 | 23.8 | 4.4 |
Endoscopic remission rate\*: percentage of participants with an endoscopic remission, defined by an endoscopic Mayo sub-score = 0. \*The endoscopic remission rate is reported with imputation.
| percentage of participants | Lusvertikimab 850 mg | Lusvertikimab 450 mg | Placebo |
|---|---|---|---|
| Endoscopic Remission Rate at Week 10 | 19.3 | 36.7 | 12.5 |
Collected over Double Blind Induction Period (from Week 0 to Week 10), Open-Label Extension Period (from Week 10 to Week 34). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lusvertikimab 850 mg Induction Period | 0/51 (0%) | 3/51 (5.9%) | 7/51 (13.7%) |
| Lusvertikimab 450 mg Induction Period | 0/36 (0%) | 3/36 (8.3%) | 9/36 (25%) |
| Placebo Induction Period | 1/49 (2%) | 3/49 (6.1%) | 12/49 (24.5%) |
| Lusvertikimab 850 mg Open-Label Extension Period | 0/120 (0%) | 10/120 (8.3%) | 49/120 (40.8%) |
| Event | Lusvertikimab 850 mg Induction Period | Lusvertikimab 450 mg Induction Period | Placebo Induction Period | Lusvertikimab 850 mg Open-Label Extension Period |
|---|---|---|---|---|
| Colitis UlcerativeGastrointestinal disorders | 0/51 | 1/36 | 1/49 | 3/120 |
| Anal UlcerGastrointestinal disorders | 0/51 | 1/36 | 0/49 | 0/120 |
| Asymptomatic Covid-19Infections and infestations | 0/51 | 1/36 | 0/49 | 0/120 |
| Chest PainGeneral disorders | 0/51 | 0/36 | 1/49 | 0/120 |
| Covid-19 PneumoniaInfections and infestations | 0/51 | 0/36 | 1/49 | 0/120 |
| Uterine LeiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/51 | 0/36 | 0/49 | 0/120 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 1/51 | 0/36 | 0/49 | 0/120 |
| Embolism VenousVascular disorders | 1/51 | 0/36 | 0/49 | 0/120 |
| Covid-19Infections and infestations | 0/51 | 0/36 | 0/49 | 2/120 |
| AnaemiaBlood and lymphatic system disorders | 0/51 | 0/36 | 0/49 | 1/120 |
| Event | Lusvertikimab 850 mg Induction Period | Lusvertikimab 450 mg Induction Period | Placebo Induction Period | Lusvertikimab 850 mg Open-Label Extension Period |
|---|---|---|---|---|
| LymphopeniaBlood and lymphatic system disorders | 2/51 | 4/36 | 1/49 | 7/120 |
| Covid-19Infections and infestations | 0/51 | 1/36 | 2/49 | 12/120 |
| Colitis UlcerativeGastrointestinal disorders | 2/51 | 1/36 | 3/49 | 10/120 |
| AnaemiaBlood and lymphatic system disorders | 0/51 | 1/36 | 2/49 | 7/120 |
| PyrexiaGeneral disorders | 0/51 | 2/36 | 1/49 | 0/120 |
| HypertensionVascular disorders | 1/51 | 0/36 | 2/49 | 0/120 |
| Upper Respiratory Tract InfectionInfections and infestations | 2/51 | 0/36 | 1/49 | 0/120 |
| NasopharyngitisInfections and infestations | 0/51 | 0/36 | 0/49 | 4/120 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/51 | 0/36 | 0/49 | 3/120 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/51 | 0/36 | 0/49 | 3/120 |
Full Analysis Set: all randomized patients with Ulcerative Colitis who received at least one dose of study treatment (2 patients excluded for Crohn's Disease).
| Age, Categorical(Participants) | Lusvertikimab 850 mg, Induction Period | Lusvertikimab 450 mg, Induction Period | Placebo, Induction Period | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 45 | 34 | 44 | 123 |
| >=65 years | 5 | 1 | 5 | 11 |
| Age, Continuous(years) | Lusvertikimab 850 mg, Induction Period | Lusvertikimab 450 mg, Induction Period | Placebo, Induction Period | Total |
|---|---|---|---|---|
| Mean | 42.5 ± 15.1 | 38.8 ± 10.5 | 42.7 ± 15.9 | 41.6 ± 14.4 |
| Sex: Female, Male(Participants) | Lusvertikimab 850 mg, Induction Period | Lusvertikimab 450 mg, Induction Period | Placebo, Induction Period | Total |
|---|---|---|---|---|
| Female | 23 | 13 | 21 | 57 |
| Male | 27 | 22 | 28 | 77 |
| Race and Ethnicity Not Collected(Participants) | Lusvertikimab 850 mg, Induction Period | Lusvertikimab 450 mg, Induction Period | Placebo, Induction Period | Total |
|---|---|---|---|---|
| Count of participants | — | — | — | 0 |
| Modified Mayo Score (MMS)(units on a scale) | Lusvertikimab 850 mg, Induction Period | Lusvertikimab 450 mg, Induction Period | Placebo, Induction Period | Total |
|---|---|---|---|---|
| Mean | 6.5 ± 1.0 | 6.0 ± 1.4 | 6.6 ± 1.2 | 6.4 ± 1.2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Oct 2020 to primary completion in Apr 2024, 42 months.
Results were first posted in Jun 2026, 2 years 1 month after primary completion.
Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 42 months is above that.
Counting every sponsor, half of 155 studies reached it within 28 months; a quarter within 22 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
OSE Immunotherapeutics